We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us

Download Mobile App





Oral COVID-19 Vaccine Proves an Effective Booster in Preclinical Trial

By HospiMedica International staff writers
Posted on 11 Jun 2021
Print article
Illustration
Illustration
An oral subunit vaccine against COVID-19 has demonstrated promising results as a booster for previously vaccinated persons in preclinical tests.

The MigVax-101 sub-unit oral vaccine being developed by MigVax Ltd. (Qiryat Shmona, Israel) was administered in a boost format following an injected S1 protein in tests carried out on rats. The vaccine elicited markedly higher neutralizing antibody titers than rats receiving an oral placebo booster. In addition, similar to a third booster injection, it elicited more effective neutralizing antibodies.

MigVax-101 is a novel oral subunit vaccine that utilizes a chimeric protein to generate three kinds of simultaneous immunological responses: mucosal, blood-based, and cell-mediated immunity. This triple-armed approach provides comprehensive protection against infection by activating all arms of the immune system, allowing for the effective eradication of the invading virus. Its epitopes were designed using computational chemistry of immunogenic epitopes in IBV, MERS, SARS-COV and SAS-COV-2, focusing on neutralizing antibodies and promoting an immune response.

As an oral vaccine, Mig-Vax-101 offers significant potential advantages over today’s first- generation injected vaccines such as ease of administration, ability to tackle new variants, delivering mucosal immunity, and ease of transport and storage. MigVax currently seeks the financing necessary for it to launch Phase 1 & 2 clinical trials, which, if successful, it believes would lead to commercial availability 9-12 months after the trials begin.

“The results of this trial increase our confidence that our MigVax-101 subunit oral vaccine will make a positive contribution to a world coming to grips with the new post-pandemic reality,” said Prof. Itamar Shalit, MigVax’s Infectious Disease Expert. “Fifteen months into the pandemic, we now see that the struggle to keep Covid under control is nearly as challenging as getting it under control to begin with. Oral boosters such as our MigVax-101 will be key enablers that will help health organizations the world over transition from ‘panic mode’ to routine, due to their ability to reduce the cost and expand the reach of ongoing vaccination programs.”

Related Links:
MigVax Ltd.

Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Silver Member
Compact 14-Day Uninterrupted Holter ECG
NR-314P
New
Neonatal Ventilator
Servo-n

Print article

Channels

Critical Care

view channel
Image: The permeable wearable electronics developed for long-term biosignal monitoring (Photo courtesy of CityUHK)

Super Permeable Wearable Electronics Enable Long-Term Biosignal Monitoring

Wearable electronics have become integral to enhancing health and fitness by offering continuous tracking of physiological signals over extended periods. This monitoring is crucial for understanding an... Read more

Surgical Techniques

view channel
Image: NTT and Olympus have begun the world\'s first joint demonstration experiment of a cloud endoscopy system (Photo courtesy of Olympus)

Cloud Endoscopy System Enables Real-Time Image Processing on the Cloud

Endoscopes, which are flexible tubes inserted into the body's natural openings for internal examination and biopsy collection, are becoming increasingly vital in medical diagnostics. Their minimal invasiveness... Read more

Patient Care

view channel
Image: The newly-launched solution can transform operating room scheduling and boost utilization rates (Photo courtesy of Fujitsu)

Surgical Capacity Optimization Solution Helps Hospitals Boost OR Utilization

An innovative solution has the capability to transform surgical capacity utilization by targeting the root cause of surgical block time inefficiencies. Fujitsu Limited’s (Tokyo, Japan) Surgical Capacity... Read more

Health IT

view channel
Image: First ever institution-specific model provides significant performance advantage over current population-derived models (Photo courtesy of Mount Sinai)

Machine Learning Model Improves Mortality Risk Prediction for Cardiac Surgery Patients

Machine learning algorithms have been deployed to create predictive models in various medical fields, with some demonstrating improved outcomes compared to their standard-of-care counterparts.... Read more

Point of Care

view channel
Image: The PATHFAST hs-cTnI-II high-sensitivity troponin assay has been developed for the PATHFAST Biomarker Analyzer (Photo courtesy of Polymedco)

POC Myocardial Infarction Test Delivers Results in 17 Minutes

Chest pain is the second leading cause of emergency department (ED) visits by adults in the United States, generating over 7 million visits annually. In the event of a suspected heart attack, physicians... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.